Thrombotic Microangiopathies

Therapy in Nephrology & Hypertension

Volumn , Issue , 2008, Pages 294-312

  Ruggenenti, Piero ^a   Noris, Marina ^b   Remuzzi, Giuseppe ^a  

^a OSPEDALI RIUNITI   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 70350209572     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-141605484-9.50028-9     Document Type: Chapter

References (94)

1. Ruggenenti P, Noris M, Remuzzi G Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 2001, 60:831-846.
2. Garg AX, Suri RS, Barrowman N, et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: A systematic review, meta-analysis, and meta-regression. JAMA 2003, 290:1360-1370.
3. Ake JA, Jelacic S, Ciol MA, et al. Relative nephroprotection during Escherichia coli O157:H7 infections: Association with intravenous volume expansion. Pediatrics 2005, 115:e673-e680.
4. Chiurchiu C, Firrincieli A, Santostefano M, et al. Adult nondiarrhea hemolytic uremic syndrome associated with Shiga toxin Escherichia coli O157:H7 bacteremia and urinary tract infection. Am J Kidney Dis 2003, 41:E4.
5. Wong CS, Jelacic S, Habeeb RL, et al. The risk of the hemolyticuremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000, 342:1930-1936.
6. Safdar N, Said A, Gangnon RE, Maki DG Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: A meta-analysis. JAMA 2002, 288:996-1001.
7. Caletti MG, Lejarraga H, Kelmansky D, Missoni M Two different therapeutic regimes in patients with sequelae of hemolyticuremic syndrome. Pediatr Nephrol 2004, 19:1148-1152.
8. Van Dyck M, Proesmans W Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome. Pediatr Nephrol 2004, 19:688-690.
9. Trachtman H, Cnaan A, Christen E, et al. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: A randomized controlled trial. JAMA 2003, 290:1337-1344.
10. Rizzoni G, Claris-Appiani A, Edefonti A, et al. Plasma infusion for hemolyticuremic syndrome in children: Results of a multicenter controlled trial. J Pediatr 1988, 112:284-290.
11. Loirat C, Veyradier A, Foulard M, et al. von Willebrand factor (vWF)-cleaving protease activity in pediatric hemolytic uremic syndrome (HUS) [abstract]. Pediatr Nephrol 2001, 16:617A.
12. Dundas S, Murphy J, Soutar RL, et al. Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak. Lancet 1999, 354:1327-1330.
13. Carter AO, Borczyk AA, Carlson JA, et al. A severe outbreak of Escherichia coli O157:H7-associated hemorrhagic colitis in a nursing home. N Engl J Med 1987, 317:1496-1500.
14. Remuzzi G, Galbusera M, Salvadori M, et al. Bilateral nephrectomy stopped disease progression in plasma-resistant hemolytic uremic syndrome with neurological signs and coma. Kidney Int 1996, 49:282-286.
15. Artz MA, Steenbergen EJ, Hoitsma AJ, et al. Renal transplantation in patients with hemolytic uremic syndrome: High rate of recurrence and increased incidence of acute rejections. Transplantation 2003, 76:821-826.
16. Loirat C, Niaudet P The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children. Pediatr Nephrol 2003, 18:1095-1101.
17. Ferraris JR, Ramirez JA, Ruiz S, et al. Shiga toxin-associated hemolytic uremic syndrome: Absence of recurrence after renal transplantation. Pediatr Nephrol 2002, 17:809-814.
18. McGraw ME, Lendon M, Stevens RF, et al. Haemolytic uraemic syndrome and the Thomsen Friedenreich antigen. Pediatr Nephrol 1989, 3:135-139.
19. Dragon-Durey MA, Loirat C, Cloarec S, et al. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005, 16:555-563.
20. Jozsi M, Strobel S, Dahse HM, et al. Anti-factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 2007, 110:1516-1518.
21. Furlan M, Robles R, Lamie B Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 1996, 87:4223-4234.
22. Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolyticuremic syndrome. N Engl J Med 1998, 339:1578-1584.
23. Tsai HM, Lian EC Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998, 339:1585-1594.
24. Veyradier A, Obert B, Houllier A, et al. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: A study of 111 cases. Blood 2001, 98:1765-1772.
25. Galbusera M, Noris M, Remuzzi G Thrombotic thrombocytopenic purpura-then and now. Semin Thromb Hemost 2006, 32:81-89.
26. Ferrari S, Scheiflinger F, Rieger M, et al. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. Blood 2007, 109:2815-2822.
27. Caletti MG, Gallo G, Gianantonio CA Development of focal segmental sclerosis and hyalinosis in hemolytic uremic syndrome. Pediatr Nephrol 1996, 10:687-692.
28. Bell WR, Braine HG, Ness PM, Kickler TS Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. N Engl J Med 1991, 325:398-403.
29. Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991, 325:393-397.
30. Byrnes JJ, Moake JL, Klug P, Periman P Effectiveness of the cryosupernatant fraction of plasma in the treatment of refractory thrombotic thrombocytopenic purpura. Am J Hematol 1990, 34:169-174.
31. Rock G, Shumak KH, Sutton DM, et al. Cryosupernatant as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura. Members of the Canadian Apheresis Group. Br J Haematol 1996, 94:383-386.
32. Hayward CP, Sutton DM, Carter WH, et al. Treatment outcomes in patients with adult thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Arch Intern Med 1994, 154:982-987.
33. Furlan M, Robles R, Solenthaler M, Lammle B Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 1998, 91:2839-2846.
34. Weiner CP Thrombotic microangiopathy in pregnancy and the postpartum period. Semin Hematol 1987, 24:119-129.
35. George JN The association of pregnancy with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2003, 10:339-344.
36. Ruggenenti P, Remuzzi G The pathophysiology and management of thrombotic thrombocytopenic purpura. Eur J Haematol 1996, 56:191-207.
37. Tsai HM, Rice L, Sarode R, et al. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura. Ann Intern Med 2000, 132:794-799.
38. Ohashi N, Yonemura K, Sugiura T, et al. Withdrawal of interferon-alpha results in prompt resolution of thrombocytopenia and hemolysis but not renal failure in hemolytic uremic syndrome caused by interferon-alpha. Am J Kidney Dis 2003, 41:E10.
39. Taylor CM Complement factor H and the haemolytic uraemic syndrome. Lancet 2001, 358:1200-1202.
40. Ruggenenti P, Galli M, Remuzzi G Hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, and antiphospholipid antibody syndromes. Immunologic Renal Diseases 2001, 1179-1208. Lippincott Williams & Wilkins, Philadelphia. E.G. Neilson, W.G. Couser (Eds.).
41. Warwicker P, Goodship TH, Donne RL, et al. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998, 53:836-844.
42. Saunders RE, Abarrategui-Garrido C, Fremeaux-Bacchi V, et al. The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: Update and integration of membrane cofactor protein and factor I mutations with structural models. Hum Mutat 2007, 28:222-234.
43. Perez-Caballero D, Gonzalez-Rubio C, et al. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet 2001, 68:478-484.
44. Neumann HP, Salzmann M, Bohnert-Iwan B, et al. Haemolytic uraemic syndrome and mutations of the factor H gene: A registry-based study of German speaking countries. J Med Genet 2003, 40:676-681.
45. Caprioli J, Noris M, Brioschi S, et al. Genetics of HUS: The impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006, 108:1267-1279.
46. Rodriguez de Cordoba S, Esparza-Gordillo J, Goicoechea de Jorge E, et al. The human complement factor H: Functional roles, genetic variations and disease associations. Mol Immunol 2004, 41:355-367.
47. Jozsi M, Manuelian T, Heinen S, et al. Attachment of the soluble complement regulator factor H to cell and tissue surfaces: Relevance for pathology. Histol Histopathol 2004, 19:251-258.
48. Venables JP, Strain L, Routledge D, et al. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med 2006, 3:e431.
49. Noris M, Brioschi S, Caprioli J, et al. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003, 362:1542-1547.
50. Richards A, Kemp EJ, Liszewski MK, et al. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2003, 100:12966-12971.
51. Goodship TH, Liszewski MK, Kemp EJ, et al. Mutations in CD46, a complement regulatory protein, predispose to atypical HUS. Trends Mol Med 2004, 10:226-231.
52. Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J, et al. Complement factor I: A susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 2004, 41:e84.
53. Kavanagh D, Kemp EJ, Mayland E, et al. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005, 16:2150-2155.
54. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2007, 104:240-245.
55. Caprioli J, Castelletti F, Bucchioni S, et al. Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: The C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Hum Mol Genet 2003, 12:3385-3395.
56. Noris M, Bucchioni S, Galbusera M, et al. Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvement. J Am Soc Nephrol 2005, 16:1177-1183.
57. Landau D, Shalev H, Levy-Finer G, et al. Familial hemolytic uremic syndrome associated with complement factor H deficiency. J Pediatr 2001, 138:412-417.
58. Cho HY, Lee BS, Moon KC, et al. Complete factor H deficiency-associated atypical hemolytic uremic syndrome in a neonate. Pediatr Nephrol 2007, 22:874-880.
59. Stratton JD, Warwicker P Successful treatment of factor H-related haemolytic uraemic syndrome. Nephrol Dial Transplant 2002, 17:684-685.
60. Bresin E, Daina E, Noris M, International Registry of Recurrent and Familial HUS/TTP, et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated haemolytic uremic syndrome: Prognostic significance of genetic background. Clin J Am Soc Nephrol 2006, 1:88-99.
61. Saland JM, Emre SH, Shneider BL, et al. Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. Am J Transplant 2006, 6:1948-1952.
62. Geelen J, van den Dries K, Roos A, et al. A missense mutation in factor I (IF) predisposes to atypical haemolytic uraemic syndrome. Pediatr Nephrol 2007, 22:371-375.
63. Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 2001, 413:488-494.
64. Ruggenenti P, Galbusera M, Cornejo RP, et al. Thrombotic thrombocytopenic purpura: Evidence that infusion rather than removal of plasma induces remission of the disease. Am J Kidney Dis 1993, 21:314-318.
65. Fujikawa K, Suzuki H, McMullen B, Chung D Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family. Blood 2001, 98:1662-1666.
66. Donadelli R, Banterla F, Galbusera M, et al. In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thromb Haemost 2006, 96:454-464.
67. Furlan M, Robles R, Morselli B, et al. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura. Thromb Haemost 1999, 81:8-13.
68. Baumgartner ER, Wick H, Maurer R, et al. Congenital defect in intracellular cobalamin metabolism resulting in homocysteinuria and methylmalonic aciduria. I. Case report and histopathology. Helv Paediatr Acta 1979, 34:465-482.
69. Van Hove JL, Van Damme-Lombaerts R, Grunewald S, et al. Cobalamin disorder Cbl-C presenting with late-onset thrombotic microangiopathy. Am J Med Genet 2002, 111:195-201.
70. Remuzzi G, Ruggenenti P, Codazzi D, et al. Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet 2002, 359:1671-1672.
71. George JN How I treat patients with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Blood 2000, 96:1223-1229.
72. Paton AW, Morona R, Paton JC A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat Med 2000, 6:265-270.
73. Pinyon RA, Paton JC, Paton AW, et al. Refinement of a therapeutic Shiga toxin-binding probiotic for human trials. J Infect Dis 2004, 189:1547-1555.
74. Takahashi M, Taguchi H, Yamaguchi H, et al. The effect of probiotic treatment with Clostridium butyricum on enterohemorrhagic Escherichia coli O157:H7 infection in mice. FEMS Immunol Med Microbiol 2004, 41:219-226.
75. Wen SX, Teel LD, Judge NA, O-Brien AD A plant-based oral vaccine to protect against systemic intoxication by Shiga toxin type 2. Proc Natl Acad Sci U S A 2006, 103:7082-7087.
76. Mulvey GL, Marcato P, Kitov PI, et al. Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands. J Infect Dis 2003, 187:640-649.
77. Matise I, Cornick NA, Booher SL, et al. Intervention with Shiga toxin (Stx) antibody after infection by Stx-producing Escherichia coli. J Infect Dis 2001, 183:347-350.
78. Loirat C, Beaufils F, Sonsino E, et al. [Treatment of childhood hemolyticuremic syndrome with urokinase. Cooperative controlled trial]. Arch Fr Pediatr 1984, 41:15-19.
79. Van Damme-Lombaerts R, Proesmans W, Van Damme B, et al. Heparin plus dipyridamole in childhood hemolyticuremic syndrome: A prospective, randomized study. J Pediatr 1998, 113:913-918.
80. Loirat C, Sonsino E, Hinglais N, et al. Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. The French Society of Paediatric Nephrology. Pediatr Nephrol 1988, 2:279-285.
81. Gianviti A, Perna A, Caringella A, et al. Plasma exchange in children with hemolyticuremic syndrome at risk of poor outcome. Am J Kidney Dis 1993, 22:264-266.
82. Italian Cooperative Group for the Study of Thrombotic Thrombocytopenic Purpura Thrombotic thrombocytopenic purpura (TTP) treatment: Italian cooperative retrospective study on 29 cases. Haematologica 1986, 71:39-43.
83. Adult hemolytic uremic syndrome with renal microangiopathy. Outcome according to therapeutic protocol in 53 cases. French Cooperative Study Group for Adult HUS. Ann Med Interne (Paris) 1992, 143(Suppl 1):27-32.
84. Henon P [Treatment of thrombotic thrombopenic purpura. Results of a multicenter randomized clinical study]. Presse Med 1991, 20:1761-1767.
85. Besbas N, Karpman D, Landau D, European Paediatric Research Group for HUS, et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int 2006, 70:423-431.
86. Espinosa G, Bucciarelli S, Cervera R, et al. Thrombotic microangiopathic haemolytic anaemia and antiphospholipid antibodies. Ann Rheum Dis 2004, 63:730-736.
87. George JN Clinical practice. Thrombotic thrombocytopenic purpura. N Engl J Med 2006, 354:1927-1935.
88. MacConnachie AA, Todd WTA Potential therapeutic agents for the prevention and treatment of haemolytic uraemic syndrome in Shiga toxin producing Escherichia coli infection. Curr Opin Infect Dis 2004, 17:479-482.
89. O-Brian JM, Barton JR Controversies with the diagnosis and management of HELLP syndrome. Clin Obstet Gynecol 2005, 48:460-477.
90. Richards A, Liszewski KM, Kavanagh D, et al. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol 2007, 44:111-122.
91. Siegler R, Oakes R Hemolytic uremic syndrome; pathogenesis, treatment, and outcome. Curr Opin Pediatr 2005, 17:200-2004.
92. Tsai HM The molecular biology of thrombotic microangiopathy. Kidney Int 2006, 70:16-23.
93. Zakarija A, Bennet C Drug-induced thrombotic microangiopathy. Semin Thromb Hemost 2005, 31:681-690.
94. Zipfel PF, Skerka C Complement dysfunction in hemolytic uremic syndrome. Curr Opin Rheumatol 2006, 18:548-555.